000 00918 a2200265 4500
005 20250517135055.0
264 0 _c20180314
008 201803s 0 0 eng d
022 _a1474-547X
024 7 _a10.1016/S0140-6736(17)30053-3
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSeror, Raphaèle
245 0 0 _aCost-effectiveness of rituximab strategies in rheumatoid arthritis.
_h[electronic resource]
260 _bLancet (London, England)
_c01 2017
300 _a365-366 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aAntirheumatic Agents
650 0 4 _aArthritis, Rheumatoid
650 0 4 _aCost-Benefit Analysis
650 0 4 _aHumans
650 0 4 _aRituximab
700 1 _aMariette, Xavier
773 0 _tLancet (London, England)
_gvol. 389
_gno. 10067
_gp. 365-366
856 4 0 _uhttps://doi.org/10.1016/S0140-6736(17)30053-3
_zAvailable from publisher's website
999 _c26831835
_d26831835